TP53_PROF: a machine learning model to predict impact of missense mutations in TP53

被引:10
|
作者
Ben-Cohen, Gil [2 ]
Doffe, Flora [3 ]
Devir, Michal [2 ]
Leroy, Bernard [4 ]
Soussi, Thierry [4 ]
Rosenberg, Shai [1 ,5 ,6 ]
机构
[1] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel
[2] Hebrew Univ Jerusalem, Jerusalem, Israel
[3] Univ Paris Saclay, Gif Sur Yvette, France
[4] Sorbonne Univ, Paris, France
[5] Hebrew Univ Jerusalem, Gaffin Ctr Neurooncol, Sharett Inst Oncol, Hadassah Med Ctr, Jerusalem, Israel
[6] Hebrew Univ Jerusalem, Wohl Inst Translat Med, Hadassah Med Ctr, Jerusalem, Israel
关键词
TP53; genetic counseling; Li-Fraumeni syndrome; precision medicine; personalized oncology; machine learning; DNA-BINDING COOPERATIVITY; P53; DATABASE; PROTEIN; OLIGOMERIZATION; RECOMMENDATIONS; CONFORMATION; REASSESSMENT; INHIBITION; LANDSCAPE;
D O I
10.1093/bib/bbab524
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Correctly identifying the true driver mutations in a patient's tumor is a major challenge in precision oncology. Most efforts address frequent mutations, leaving medium- and low-frequency variants mostly unaddressed. For TP53, this identification is crucial for both somatic and germline mutations, with the latter associated with the Li-Fraumeni syndrome (LFS), a multiorgan cancer predisposition. We present TP53_PROF (prediction of functionality), a gene specific machine learning model to predict the functional consequences of every possible missense mutation in TP53, integrating human cell- and yeast-based functional assays scores along with computational scores. Variants were labeled for the training set using well-defined criteria of prevalence in four cancer genomics databases. The model's predictions provided accuracy of 96.5%. They were validated experimentally, and were compared to population data, LFS datasets, ClinVar annotations and to TCGA survival data. Very high accuracy was shown through all methods of validation. TP53_PROF allows accurate classification of TP53 missense mutations applicable for clinical practice. Our gene specific approach integrated machine learning, highly reliable features and biological knowledge, to create an unprecedented, thoroughly validated and clinically oriented classification model. This approach currently addresses TP53 mutations and will be applied in the future to other important cancer genes.
引用
收藏
页数:19
相关论文
共 50 条
  • [31] TP53 mutations and rituximab-CHOP
    Gisselbrecht, Christian
    BLOOD, 2012, 120 (19) : 3867 - 3869
  • [32] TP53 mutations in epithelial ovarian cancer
    Zhang, Yu
    Cao, Lan
    Daniel Nguyen
    Lu, Hua
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 (06) : 650 - 663
  • [33] TP53 Mutations in Breast and Ovarian Cancer
    Silwal-Pandit, Laxmi
    Langerod, Anita
    Borresen-Dale, Anne-Lise
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2017, 7 (01):
  • [34] TP53 mutations and polymorphisms in primary myelofibrosis
    Raza, Sania
    Viswanatha, David
    Frederick, Lori
    Lasho, Terra
    Finke, Christy
    Knudson, Ryan
    Ketterling, Rhett
    Pardanani, Animesh
    Tefferi, Ayalew
    AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (02) : 204 - 206
  • [35] TP53 mutations and Azacitidine treatment: To be or not to be related?
    Rigolin, Gian Matteo
    Cuneo, Antonio
    LEUKEMIA RESEARCH, 2014, 38 (07) : 727 - 728
  • [36] Three germline mutations in the TP53 gene
    Cornelis, RS
    vanVliet, M
    vandeVijver, MJ
    Vasen, HFA
    Voute, PA
    Top, B
    Khan, PM
    Devilee, P
    Cornelisse, CJ
    HUMAN MUTATION, 1997, 9 (02) : 157 - 163
  • [37] TP53 Mutations in Canine Brain Tumors
    York, D.
    Higgins, R. J.
    LeCouteur, R. A.
    Wolfe, A. N.
    Grahn, R.
    Olby, N.
    Campbell, M.
    Dickinson, P. J.
    VETERINARY PATHOLOGY, 2012, 49 (05) : 796 - 801
  • [38] Role of TP53 Mutations in Vulvar Carcinomas
    Choschzick, Matthias
    Hantaredja, Widianto
    Tennstedt, Pierre
    Gieseking, Frederike
    Woelber, Linn
    Simon, Ronald
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2011, 30 (05) : 497 - 504
  • [39] Clinical Outcomes of TP53 Mutations in Cancers
    Robles, Ana I.
    Jen, Jin
    Harris, Curtis C.
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2016, 6 (09):
  • [40] Targeting TP53 Mutations in Myelodysplastic Syndromes
    Hunter, Anthony M.
    Sallman, David A.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2020, 34 (02) : 421 - +